Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Mauro, Fiacchini"'
Autor:
Marta Stanzani, Russell E Lewis, Mauro Fiacchini, Paolo Ricci, Fabio Tumietto, Pierluigi Viale, Simone Ambretti, Michele Baccarani, Michele Cavo, Nicola Vianelli
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e75531 (2013)
BACKGROUND: A risk score for invasive mold disease (IMD) in patients with hematological malignancies could facilitate patient screening and improve the targeted use of antifungal prophylaxis. METHODS: We retrospectively analyzed 1,709 hospital admiss
Externí odkaz:
https://doaj.org/article/03f5d6d6ca424818a9ee768390809fc9
Autor:
Giuseppe Bandini, Francesco Lauria, Patrizio Mazza, Filippo Gherlinzoni, Giovanni Poletti, Maurizio Cantore, Stefano Pileri, Mauro Fiacchini, Sante Tura
Publikováno v:
Scandinavian Journal of Haematology. 35:123-131
248 patients with non-Hodgkin lymphomas (NHL) were retrospectively analysed in an attempt to elucidate the risk factors, the prognostic importance and the therapeutic implications of blood involvement. Bone marrow involvement and large spleen were si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::002c85149a82717aadc165376e486951
https://doi.org/10.1111/j.1600-0609.1985.tb01560.x
https://doi.org/10.1111/j.1600-0609.1985.tb01560.x
Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α-interferon
Autor:
Antonio De Vivo, Enrico Montefusco, Domenico Russo, E Trabacchi, Michele Baccarani, Mauro Fiacchini, Gianantonio Rosti, Mario Tiribelli, Francesca Bonifazi
Publikováno v:
British Journal of Haematology. 111:587-595
As it has been shown that α-interferon (αIFN) treatment modifies the survival of chronic myeloid leukaemia (CML) patients in comparison with conventional chemotherapy, a new prognostic score was devised with the aim of providing a treatment-adapted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::079f953b90b05fa4912c05bef766e229
https://doi.org/10.1111/j.1365-2141.2000.02366.x
https://doi.org/10.1111/j.1365-2141.2000.02366.x
Autor:
Mauro Fiacchini, Giovanni Rosti, Michele Baccarani, Enrico Montefusco, E Trabacchi, Francesca Bonifazi, de Vivo A, Mario Tiribelli, Domenico Russo
Publikováno v:
British Journal of Haematology. 111:587-595
As it has been shown that alpha-interferon (alphaIFN) treatment modifies the survival of chronic myeloid leukaemia (CML) patients in comparison with conventional chemotherapy, a new prognostic score was devised with the aim of providing a treatment-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::508d56bd02066febc91ecba94550c5a2
https://doi.org/10.1046/j.1365-2141.2000.02366.x
https://doi.org/10.1046/j.1365-2141.2000.02366.x
Autor:
Mauro Fiacchini, Stefania Grimaz, Gabriella Trani, Michela Cerno, Daniela Damiani, Michele Baccarani, Laura Infanti, Antonella Geromin, Renato Fanin, Federico Silvestri, Cristina Rinaldi, Mariagrazia Michieli, Savignano C
Publikováno v:
Scopus-Elsevier
Although a large amount of data is available on the effects of filgrastim (granulocyte colony-stimulating factor [G-CSF]) on the mobilization of stem cells in the circulation, data concerning its effects on bone marrow (BM) harvesting is scarce and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ac56e4fdc1b1cb1618ec8bab8ff0619
https://doi.org/10.1182/blood.v90.1.36
https://doi.org/10.1182/blood.v90.1.36
Autor:
Fabio Tumietto, Mauro Fiacchini, Pierluigi Viale, Nicola Vianelli, Marta Stanzani, Russell E. Lewis, Michele Cavo, Paolo Ricci, Simone Ambretti, Michele Baccarani
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e75531 (2013)
PLoS ONE
PLoS ONE
BACKGROUND: A risk score for invasive mold disease (IMD) in patients with hematological malignancies could facilitate patient screening and improve the targeted use of antifungal prophylaxis. METHODS: We retrospectively analyzed 1,709 hospital admiss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a86a1cf40e797850f34563a656c07d8
http://europepmc.org/articles/PMC3784450?pdf=render
http://europepmc.org/articles/PMC3784450?pdf=render
Autor:
V De Sanctis, Mauro Fiacchini, Pier Luigi Zinzani, Tura S, Maria Paola Martelli, Marco Vignetti, Giovanna Meloni, F Calabresi, M F Martelli, Franco Gherlinzoni, Franco Mandelli, Giuseppe Papa
Publikováno v:
Journal of Clinical Oncology. 14:534-542
PURPOSE To evaluate, in a prospective multicentric study, the efficacy of a conventional salvage chemotherapy (dexamethasone, cisplatin, and cytarabine [DHAP]) versus high-dose chemotherapy (carmustine, etoposide, cytarabine, and cyclophosphamide [BE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f25ef55835aa4292dbd463ca53bba358
https://doi.org/10.1200/jco.1996.14.2.534
https://doi.org/10.1200/jco.1996.14.2.534
Autor:
Emanuela Ottaviani, Mauro Fiacchini, Federica Salmi, Francesca Palandri, Michele Baccarani, Giovanni Martinelli, Lucia Catani, Nicola Polverelli, Nicola Vianelli
Publikováno v:
Leukemialymphoma. 50(2)
The JAK2(V617F) mutation occurs in 50% of patients with essential thrombocythemia (ET). We investigated the correlation between the JAK2(V617F) mutation and clinical and laboratory characteristics, thrombohemorrhagic risk and incidence of disease evo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3842205edf2af48e0a5a46f6e118ca26
https://pubmed.ncbi.nlm.nih.gov/19235012
https://pubmed.ncbi.nlm.nih.gov/19235012
Autor:
Lucia Pantani, Patrizia Tosi, Antonietta Falcone, Maria Teresa Petrucci, Paola Tacchetti, Sara Bringhen, Paola Agostini, Chiara Nozzoli, Antonio Ledda, Claudia Cellini, Elena Zamagni, Luca Baldini, Tonino Spadano, Vittorio Montefusco, Francesco Di Raimondo, Franco Narni, Massimo Offidani, Tommaso Caravita, Norbert Pescosta, Mauro Fiacchini, Michele Baccarani, Monica Galli, Renato Zambello, Claudia Crippa, Francesca Patriarca, Michele Cavo, Luciano Masini
Abstract 351 Introduction A phase III study of melphalan (200 mg/m2)-based double autologous stem-cell transplantation (ASCT) incorporating thalidomide (T) and dexamethasone (D) with or without the addition of bortezomib (V) as first-line therapy for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b7a8c25328ab5d82b833c82d34d20d5
http://hdl.handle.net/20.500.11769/75901
http://hdl.handle.net/20.500.11769/75901
Autor:
Paola Tacchetti, Patrizia Tosi, Michele Cavo, Annamaria Brioli, Delia Cangini, Giuliana Leopardi, Elena Zamagni, Alessandro Gozzetti, Antonio Ledda, Francesco Casulli, Nicoletta Testoni, Massimo Offidani, Carolina Terragna, Affra Carubelli, Alessandro Petrucci, Lucia Pantani, Claudia Cellini, Michele Baccarani, Silvestro Volpe, Giulia Perrone, Chiara Nicci, Luciano Masini, Francesco Di Raimondo, Michela Ceccolini, Catello Califano, Francesca Patriarca, Lucio Catalano, Mauro Fiacchini
Publikováno v:
ResearcherID
Abstract 349 We report here on the final analysis of the multicenter phase II “Bologna 2002” study which incorporated thal-dex into double ASCT with high-dose melphalan (200 mg/m2) as front-line therapy for younger patients with symptomatic multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa59c7796c3e930643ae76ba1f60e3d
http://hdl.handle.net/20.500.11769/75921
http://hdl.handle.net/20.500.11769/75921